Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Henagliflozin on Cardiac Structure, Function and Biomarkers of Heart Failure in Patients With Persistent Atrial Fibrillation

NCT05252624 is registered in ClinicalTrials.gov with Beijing Anzhen Hospital as lead sponsor.

NCT NCT05252624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05252624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Henagliflozin on Cardiac Structure, Function and Biomarkers of Heart Failure in Patients With Persistent Atrial Fibrillation
Lead sponsor
Beijing Anzhen Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
September 1, 2022
Completion date
September 30, 2023
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation